Cannabis in Brazil

The year 2024 was one of the most dynamic for the cannabis industry in Brazil. In the medical segment, which is amongst the top 10 global markets in USD value, cannabis-based medications started to be distributed through the public health system of Brazil’s most populous state. Moreover, ANVISA (Brazil’s Health Regulatory Agency) defined and approved the quality standards for female and dry flowers that are to be used to produce cannabis-based medications, and the Superior Court of Justice allow...

Euromonitor International's Cannabis in Brazil market report offers a comprehensive guide to the size and shape of this emerging market opportunity at a national level. It provides the latest retail sales data (historic date range), allowing you to identify the key cannabinoid categories driving growth. It outlines the regulatory, cultural and commercial context and offers strategic analysis of key factors influencing the market – legislative developments both current and future, economic/lifestyle influences, illicit consumption, product innovation, distribution and pricing trends. Forecasts to 2029 illustrate how the market is set to expand and change.

Product coverage: Adult-Use Cannabis, CBD & Other Non-Intoxicating Cannabinoids, Medical Cannabis.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Cannabis market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.